Back to results
US 2003/0225127 A1Published application
Heterocyclic sulfonamide derivatives
OwnerDavid Michael Bender, Scott Louis Forman +4inventors
InventorsDavid Michael Bender, Scott Louis Forman, Winton Dennis Jones, Daryl Lynn Smith, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
Life of this patent
Estimating the term…
Abstract
The present invention provides certain heterocyclic sulfonamide derivatives of formula (I): useful for potentiating glutamate receptor function in a patient and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.
Claims17
A compound of the formula:
- 53
- wherein
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR7R8;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, or —OR9;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- and
- Q is selected from the following:
- 54
- wherein
- R5 represents hydrogen or (1-6C)alkyl;
- Y represents CH2CH2, CR10R11, NR6, S, or O;
- Z represents O, S, or NH;
- R6 represents hydrogen or (1-6C)alkyl;
- R7 and R8 each independently represent hydrogen or (1-4C)alkyl;
- R9 represents hydrogen or (1-4C)alkyl;
- and
- R10 and R11 each independently represent hydrogen or (1-4C)alkyl;
- or a pharmaceutically acceptable salt thereof.
15 more elements
A compound selected from the group consisting of:
- 6-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]-3-hydrobenzothiazol-2-one;
- 6-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]-3-hydrobenzoxazol-2-one;
- 5-[4-(1-methyl-2-([(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-one;
- 5-[4-((1R)-1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-one;
- 5-[4-((1S)-1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-one;
- 6-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-one;
- 6-[4-((1R)-1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]indolin-2-one;
- 6-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]-1,3,4-trihydroquinolin-2-one;
- and
- 5-[4-(1-methyl-2-{[(methylethyl)sulfonyl]amino}ethyl)phenyl]-3-hydrobenzimidazol-2-one;
- or a pharmaceutically acceptable salt thereof.
8 more elements
A method of potentiating glutamate receptor function in a patient, which comprises administering to said patient an effective amount of a compound of formula:
- 55
- wherein
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR7R8;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, or —OR9;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- and
- Q is selected from the following:
- 56
- wherein
- R5 represents hydrogen or (1-6C)alkyl;
- Y represents CH2CH2, CR10R11, NR6, S, or O;
- Z represents O, S, or NH;
- R6 represents hydrogen or (1-6C)alkyl;
- R7 and R8 each independently represent hydrogen or (1-4C)alkyl;
- R9 represents hydrogen or (1-4C)alkyl;
- and
- R10 and R11 each independently represent hydrogen or (1-4C)alkyl;
- or a pharmaceutically acceptable salt thereof.
15 more elements
A method of treating a cognitive disorder;
- Alzheimer's disease, a neuro-degenerative disorder;
- age-related dementia;
- age-induced memory impairment;
- movement disorder;
- reversal of a drug-induced state;
- depression;
- attention deficit disorder;
- attention deficit hyperactivity disorder;
- psychosis;
- cognitive deficits associated with psychosis;
- drug-induced psychosis, or stroke in a patient, which comprises administering to a patient an effective amount of a compound of formula:
- 57
- wherein
- R1 represents (1-6C)alkyl, (2-6C)alkenyl, or NR7R8;
- R2 and R3 each independently represent hydrogen, (1-4C)alkyl, or —OR9;
- R4a and R4b each independently represent hydrogen, (1-4C) alkyl, (1-4C)alkoxy, I, Br, Cl, or F;
- and
- Q is selected from the following:
- 58
- wherein
- R5 represents hydrogen or (1-6C)alkyl;
- Y represents CH2CH2, CR10R11, NR6, S, or O;
- Z represents O, S, or NH;
- R6 represents hydrogen or (1-6C)alkyl;
- R7 and R8 each independently represent hydrogen or (1-4C)alkyl;
- R9 represents hydrogen or (1-4C)alkyl;
- and
- R10 and R11 each independently represent hydrogen or (1-4C)alkyl;
- or a pharmaceutically acceptable salt thereof.
26 more elements
Dependencies are inferred from the claim text.